1-3 of 3
Lennart Friis-Hansen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impaired CD163-mediated hemoglobin-scavenging and severe toxic symptoms in patients treated with gemtuzumab ozogamicin

Brief Report
Maciej Bogdan Maniecki, Henrik Hasle, Lennart Friis-Hansen, Birgitte Lausen, Ove Juul Nielsen, Knud Bendix, Søren Kragh Moestrup, Holger Jon Møller
Journal: Blood
Blood (2008) 112 (4): 1510–1514.
https://doi.org/10.1182/blood-2007-09-114165
Published: 2008
Includes: Supplemental data
Journal Articles

Impaired CD163 Mediated Hemoglobin-Scavenging and Hemolytic Crisis in Patients Treated with CD33 Targeted Chemotherapy (Gemtuzumab Ozogamicin, Mylotarg™).

Maciej B. Maniecki, MHSc, Henrik Hasle, MD, PHD, Lennart Friis-Hansen, MD, PHD, Birgitte Lausen, MD, PHD, Ove J. Nielsen, MD, PHD, Knud Bendix, MD, PHD, Soren K. Moestrup, MD, PHD, Holger J. Moller, MD, PHD
Journal: Blood
Blood (2007) 110 (11): 3684.
https://doi.org/10.1182/blood.V110.11.3684.3684
Published: 2007
Journal Articles

The Predictive Value of Gene Expression Profiles for Acute Graft-Versus-Host Disease after Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning for Hematological Malignancy.

Tania N. Masmas, MD, Lennart Friis-Hansen, M.D., Jens Vilstrup Johansen, M.S., Soren Lykke Petersen, M.D., Brian T. Kornblit, M.D., Ole Winther, M.S., Finn Cilius Nielsen, M.D., Lars Vindelov, M.D.
Journal: Blood
Blood (2007) 110 (11): 1079.
https://doi.org/10.1182/blood.V110.11.1079.1079
Published: 2007